Fat malabsorption in short bowel syndrome: A review of pathophysiology and management.
Thomas I HirschSarah Ziqi WangScott C FligorMikayla QuigleyKathleen M GuraMark PuderSavas T TsikisPublished in: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition (2024)
Fat malabsorption is central to the pathophysiology of short bowel syndrome (SBS). It occurs in patients with insufficient intestinal surface area and/or function to maintain metabolic and growth demands. Rapid intestinal transit and impaired bile acid recycling further contribute to fat malabsorption. A significant portion of patients require parenteral nutrition (PN) for their survival but may develop sepsis and liver dysfunction as a result. Despite advancements in the treatment of SBS, fat malabsorption remains a chronic issue for this vulnerable patient population. Peer-reviewed literature was assessed on the topic of fat malabsorption in SBS. Current management of patients with SBS involves dietary considerations, PN management, antidiarrheals, glucagon-like peptide 2 agonists, and multidisciplinary teams. Clinical trials have focused on improving intestinal fat absorption by facilitating fat digestion with pancreatic enzymes. Targeting fat malabsorption in SBS is a potential pathway to improving lifestyle and reducing morbidity and mortality in this rare disease.
Keyphrases
- adipose tissue
- fatty acid
- clinical trial
- randomized controlled trial
- systematic review
- type diabetes
- acute kidney injury
- newly diagnosed
- cardiovascular disease
- ejection fraction
- weight loss
- intensive care unit
- oxidative stress
- quality improvement
- drug delivery
- study protocol
- double blind
- septic shock
- human health
- phase iii